Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice
Citations Over TimeTop 10% of 2015 papers
Abstract
Insulin-degrading enzyme (IDE) is a protease that cleaves insulin and other bioactive peptides such as amyloid-β. Knockout and genetic studies have linked IDE to Alzheimer's disease and type-2 diabetes. As the major insulin-degrading protease, IDE is a candidate drug target in diabetes. Here we have used kinetic target-guided synthesis to design the first catalytic site inhibitor of IDE suitable for in vivo studies (BDM44768). Crystallographic and small angle X-ray scattering analyses show that it locks IDE in a closed conformation. Among a panel of metalloproteases, BDM44768 selectively inhibits IDE. Acute treatment of mice with BDM44768 increases insulin signalling and surprisingly impairs glucose tolerance in an IDE-dependent manner. These results confirm that IDE is involved in pathways that modulate short-term glucose homeostasis, but casts doubt on the general usefulness of the inhibition of IDE catalytic activity to treat diabetes.
Related Papers
- → The ventromedial hypothalamic nucleus: watchdog of whole-body glucose homeostasis(2022)45 cited
- → CNS GLP-1 regulation of peripheral glucose homeostasis(2008)64 cited
- → Astrocytes in the nucleus of the solitary tract are activated by low glucose or glucoprivation: evidence for glial involvement in glucose homeostasis(2013)48 cited
- → The impact of hypoxia exposure on glucose homeostasis in metabolically compromised humans: A systematic review(2021)23 cited
- → The Measurement of Whole-Body Glucose Homeostasis in Mice(2020)1 cited